Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
David Dongkyung Kim, Candice S Kung, David L Perez
No abstract text is available yet for this article.
April 9, 2021: JAMA Neurology
#2
(no author information available yet)
No abstract text is available yet for this article.
April 5, 2021: JAMA Neurology
#3
Roel Haeren, Rahul Raj, Mika Niemelä
No abstract text is available yet for this article.
April 5, 2021: JAMA Neurology
#4
Samuel Harrison Marcum
No abstract text is available yet for this article.
April 5, 2021: JAMA Neurology
#5
Erika A Petersen, Thomas G Stauss, James A Scowcroft, Elizabeth S Brooks, Judith L White, Shawn M Sills, Kasra Amirdelfan, Maged N Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis G Patterson, Kostandinos C Tsoulfas, Michael J Creamer, Vincent Galan, Richard H Bundschu, Christopher A Paul, Neel D Mehta, Heejung Choi, Dawood Sayed, Shivanand P Lad, David J DiBenedetto, Khalid A Sethi, Johnathan H Goree, Matthew T Bennett, Nathan J Harrison, Atef F Israel, Paul Chang, Paul W Wu, Gennady Gekht, Charles E Argoff, Christian E Nasr, Rod S Taylor, Jeyakumar Subbaroyan, Bradford E Gliner, David L Caraway, Nagy A Mekhail
Importance: Many patients with diabetic peripheral neuropathy experience chronic pain and inadequate relief despite best available medical treatments. Objective: To determine whether 10-kHz spinal cord stimulation (SCS) improves outcomes for patients with refractory painful diabetic neuropathy (PDN). Design, Setting, and Participants: The prospective, multicenter, open-label SENZA-PDN randomized clinical trial compared conventional medical management (CMM) with 10-kHz SCS plus CMM...
April 5, 2021: JAMA Neurology
#6
Elan L Guterman, John P Betjemann, Alex Aimetti, Justin W Li, Zheng Wang, David Yin, Joseph Hulihan, Thomas Lyons, Gavin Miyasato, Adam Strzelczyk
Importance: Status epilepticus (SE) is associated with poor clinical outcomes and high cost. Increased levels of refractory SE require treatment with additional medications and carry increased morbidity and mortality, but the associations between SE refractoriness, clinical outcomes, and cost remain poorly characterized. Objective: To examine differences in clinical outcomes and costs associated with hospitalization for SE of varying refractoriness. Design, Setting, and Participants: A cross-sectional study of 43 988 US hospitalizations from January 1, 2016 to December 31, 2018, was conducted, including patients with primary or secondary International Statistical Classification of Diseases, Tenth Revision, diagnosis specifying "with status epilepticus...
April 5, 2021: JAMA Neurology
#7
Ludwig Kappos, Robert J Fox, Michel Burcklen, Mark S Freedman, Eva K Havrdová, Brian Hennessy, Reinhard Hohlfeld, Fred Lublin, Xavier Montalban, Carlo Pozzilli, Tatiana Scherz, Daniele D'Ambrosio, Philippe Linscheid, Andrea Vaclavkova, Magdalena Pirozek-Lawniczek, Hilke Kracker, Till Sprenger
Importance: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). Objective: To compare the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with RMS. Design, Setting, and Participants: This multicenter, double-blind, active-comparator, superiority randomized clinical trial enrolled patients from April 27, 2015, to May 16, 2019, who were aged 18 to 55 years and had been diagnosed with multiple sclerosis per 2010 McDonald criteria, with a relapsing course from the onset, Expanded Disability Status Scale (EDSS) scores of 0 to 5...
March 29, 2021: JAMA Neurology
#8
Claudia H Kawas, María M Corrada, Rachel A Whitmer
No abstract text is available yet for this article.
March 29, 2021: JAMA Neurology
#9
Sophie N M Binks, Michele Veldsman, Ava Easton, M Isabel Leite, David Okai, Masud Husain, Sarosh R Irani
No abstract text is available yet for this article.
March 29, 2021: JAMA Neurology
#10
Elena Tsoy, Rachel E Kiekhofer, Elan L Guterman, Boon Lead Tee, Charles C Windon, Karen A Dorsman, Serggio C Lanata, Gil D Rabinovici, Bruce L Miller, Amy J H Kind, Katherine L Possin
Importance: The US aging population is rapidly becoming more racially and ethnically diverse. Early diagnosis of dementia is a health care priority. Objective: To examine the associations between race/ethnicity and timeliness of dementia diagnosis and comprehensiveness of diagnostic evaluation. Design, Setting, and Participants: This retrospective cross-sectional study used 2013-2015 California Medicare fee-for-service data to examine the associations of race/ethnicity, individual factors, and contextual factors with the timeliness and comprehensiveness of dementia diagnosis...
March 29, 2021: JAMA Neurology
#11
(no author information available yet)
No abstract text is available yet for this article.
March 22, 2021: JAMA Neurology
#12
Yi Li, Wesley K Thompson, Chase Reuter, Ryan Nillo, Terry Jernigan, Anders Dale, Leo P Sugrue, Julian Brown, Robert F Dougherty, Andreas Rauschecker, Jeffrey Rudie, Deanna M Barch, Vince Calhoun, Donald Hagler, Sean Hatton, Jody Tanabe, Andrew Marshall, Kenneth J Sher, Steven Heeringa, Robert Hermosillo, Marie T Banich, Lindsay Squeglia, James Bjork, Robert Zucker, Michael Neale, Megan Herting, Chandni Sheth, Rebeka Huber, Gloria Reeves, John M Hettema, Katia Delrahim Howlett, Christine Cloak, Arielle Baskin-Sommers, Kristina Rapuano, Raul Gonzalez, Nicole Karcher, Angela Laird, Fiona Baker, Regina James, Elizabeth Sowell, Anthony Dick, Samuel Hawes, Matthew Sutherland, Kara Bagot, Jerzy Bodurka, Florence Breslin, Amanda Morris, Martin Paulus, Kevin Gray, Elizabeth Hoffman, Susan Weiss, Nishadi Rajapakse, Meyer Glantz, Bonnie Nagel, Sarah Feldstein Ewing, Aimee Goldstone, Adolf Pfefferbaum, Devin Prouty, Monica Rosenberg, Susan Bookheimer, Susan Tapert, Maria Infante, Joanna Jacobus, Jay Giedd, Paul Shilling, Natasha Wade, Kristina Uban, Frank Haist, Charles Heyser, Clare Palmer, Joshua Kuperman, John Hewitt, Linda Cottler, Amal Isaiah, Linda Chang, Sarah Edwards, Thomas Ernst, Mary Heitzeg, Leon Puttler, Chandra Sripada, William Iacono, Monica Luciana, Duncan Clark, Beatriz Luna, Claudiu Schirda, John Foxe, Edward Freedman, Michael Mason, Erin McGlade, Perry Renshaw, Deborah Yurgelun-Todd, Matthew Albaugh, Nicholas Allgaier, Bader Chaarani, Alexandra Potter, Masha Ivanova, Krista Lisdahl, Elizabeth Do, Hermine Maes, Ryan Bogdan, Andrey Anokhin, Nico Dosenbach, Paul Glaser, Andrew Heath, Betty J Casey, Dylan Gee, Hugh P Garavan, Gaya Dowling, Sandra Brown
Importance: Incidental findings (IFs) are unexpected abnormalities discovered during imaging and can range from normal anatomic variants to findings requiring urgent medical intervention. In the case of brain magnetic resonance imaging (MRI), reliable data about the prevalence and significance of IFs in the general population are limited, making it difficult to anticipate, communicate, and manage these findings. Objectives: To determine the overall prevalence of IFs in brain MRI in the nonclinical pediatric population as well as the rates of specific findings and findings for which clinical referral is recommended...
March 22, 2021: JAMA Neurology
#13
S Andrew Josephson
No abstract text is available yet for this article.
March 22, 2021: JAMA Neurology
#14
Lizhang Chen, Hua Cao, Muke Zhou
No abstract text is available yet for this article.
March 22, 2021: JAMA Neurology
#15
Amber Salter, Robert J Fox, Scott D Newsome, June Halper, David K B Li, Pamela Kanellis, Kathleen Costello, Bruce Bebo, Kottil Rammohan, Gary R Cutter, Anne H Cross
Importance: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections. Objective: To examine outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with MS. Design, Setting, and Participants: This analysis used deidentified, cross-sectional data on patients with MS and SARS-CoV-2 infection reported by health care professionals in North American academic and community practices between April 1, 2020, and December 12, 2020, in the COVID-19 Infections in MS Registry...
March 19, 2021: JAMA Neurology
#16
Arpan Patel, James Sul, Marc L Gordon, Jared Steinklein, Shayna Sanguinetti, Bidyut Pramanik, Dushyant Purohit, Vahram Haroutunian, Alex Williamson, Igor Koralnik, Asaff Harel
Importance: Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus that has no proven effective treatment. Although rare cases of PML have occurred with other anti-CD20 therapies, there had been no prior cases associated with ocrelizumab. Objective: To report the first ever case of PML occurring with ocrelizumab monotherapy in a patient with progressive multiple sclerosis without prior immunomodulation. Design, Setting, and Participant: This case was reported from an academic medical center...
March 16, 2021: JAMA Neurology
#17
David J Seiffge, Duncan Wilson, Teddy Yuan-Hao Wu
No abstract text is available yet for this article.
March 15, 2021: JAMA Neurology
#18
Roser Velasco, Macarena Villagrán, Maria Jové, Marta Simó, Noelia Vilariño, Montserrat Alemany, Ramon Palmero, Maria Mercedes Martínez-Villacampa, Ernest Nadal, Jordi Bruna
Importance: Encephalitis is a severe immune-related adverse event secondary to treatment with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) ranges from disease that resolves fully to lethal forms. Moreover, ICIs may unmask a paraneoplastic encephalitis. To our knowledge, the factors associated with ICI-iE prognosis are unknown. Objectives: To evaluate the presentation of ICI-iE and to identify features helpful in assessing outcomes...
March 15, 2021: JAMA Neurology
#19
Adnan I Qureshi, Wei Huang, Iryna Lobanova
No abstract text is available yet for this article.
March 15, 2021: JAMA Neurology
#20
Chakrapani Mahabala, Prabodh Varma, Ashok Shenoy
No abstract text is available yet for this article.
March 15, 2021: JAMA Neurology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
